153 related articles for article (PubMed ID: 31826047)
21. Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer.
Umeh-Garcia M; O'Geen H; Simion C; Gephart MH; Segal DJ; Sweeney CA
Br J Cancer; 2022 Aug; 127(3):436-448. PubMed ID: 35440669
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase inhibitors promote the expression of ATP2A3 gene in breast cancer cell lines.
Contreras-Leal E; Hernández-Oliveras A; Flores-Peredo L; Zarain-Herzberg Á; Santiago-García J
Mol Carcinog; 2016 Oct; 55(10):1477-85. PubMed ID: 26331238
[TBL] [Abstract][Full Text] [Related]
23. CHST11 gene expression and DNA methylation in breast cancer.
Herman D; Leakey TI; Behrens A; Yao-Borengasser A; Cooney CA; Jousheghany F; Phanavanh B; Siegel ER; Safar AM; Korourian S; Kieber-Emmons T; Monzavi-Karbassi B
Int J Oncol; 2015 Mar; 46(3):1243-51. PubMed ID: 25586191
[TBL] [Abstract][Full Text] [Related]
24. Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue.
Spizzo G; Gastl G; Obrist P; Fong D; Haun M; Grünewald K; Parson W; Eichmann C; Millinger S; Fiegl H; Margreiter R; Amberger A
Cancer Lett; 2007 Feb; 246(1-2):253-61. PubMed ID: 16624485
[TBL] [Abstract][Full Text] [Related]
25. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
26. Potentiation of growth inhibition and epigenetic modulation by combination of green tea polyphenol and 5-aza-2'-deoxycytidine in human breast cancer cells.
Tyagi T; Treas JN; Mahalingaiah PK; Singh KP
Breast Cancer Res Treat; 2015 Feb; 149(3):655-68. PubMed ID: 25663548
[TBL] [Abstract][Full Text] [Related]
27. HLJ1 (DNAJB4) Gene Is a Novel Biomarker Candidate in Breast Cancer.
Acun T; Doberstein N; Habermann JK; Gemoll T; Thorns C; Oztas E; Ried T
OMICS; 2017 May; 21(5):257-265. PubMed ID: 28481734
[TBL] [Abstract][Full Text] [Related]
28. Molecular Subtype-Specific Expression of MicroRNA-29c in Breast Cancer Is Associated with CpG Dinucleotide Methylation of the Promoter.
Poli E; Zhang J; Nwachukwu C; Zheng Y; Adedokun B; Olopade OI; Han YJ
PLoS One; 2015; 10(11):e0142224. PubMed ID: 26539832
[TBL] [Abstract][Full Text] [Related]
29. Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer.
Fujikane T; Nishikawa N; Toyota M; Suzuki H; Nojima M; Maruyama R; Ashida M; Ohe-Toyota M; Kai M; Nishidate T; Sasaki Y; Ohmura T; Hirata K; Tokino T
Breast Cancer Res Treat; 2010 Aug; 122(3):699-710. PubMed ID: 19859801
[TBL] [Abstract][Full Text] [Related]
30. Factors affecting the persistence of drug-induced reprogramming of the cancer methylome.
Bell JS; Kagey JD; Barwick BG; Dwivedi B; McCabe MT; Kowalski J; Vertino PM
Epigenetics; 2016 Apr; 11(4):273-87. PubMed ID: 27082926
[TBL] [Abstract][Full Text] [Related]
31. Global identification of genes regulated by estrogen signaling and demethylation in MCF-7 breast cancer cells.
Putnik M; Zhao C; Gustafsson JÅ; Dahlman-Wright K
Biochem Biophys Res Commun; 2012 Sep; 426(1):26-32. PubMed ID: 22902638
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of DNMT1 and ERRα crosstalk suppresses breast cancer via derepression of IRF4.
Vernier M; McGuirk S; Dufour CR; Wan L; Audet-Walsh E; St-Pierre J; Giguère V
Oncogene; 2020 Oct; 39(41):6406-6420. PubMed ID: 32855526
[TBL] [Abstract][Full Text] [Related]
33. Promoter CpG-Site Methylation of the KAI1 Metastasis Suppressor Gene Contributes to Its Epigenetic Repression in Prostate Cancer.
Lee J; Lee MS; Jeoung DI; Kim YM; Lee H
Prostate; 2017 Mar; 77(4):350-360. PubMed ID: 27813113
[TBL] [Abstract][Full Text] [Related]
34. Critical role of the MCAM-ETV4 axis triggered by extracellular S100A8/A9 in breast cancer aggressiveness.
Chen Y; Sumardika IW; Tomonobu N; Kinoshita R; Inoue Y; Iioka H; Mitsui Y; Saito K; Ruma IMW; Sato H; Yamauchi A; Murata H; Yamamoto KI; Tomida S; Shien K; Yamamoto H; Soh J; Futami J; Kubo M; Putranto EW; Murakami T; Liu M; Hibino T; Nishibori M; Kondo E; Toyooka S; Sakaguchi M
Neoplasia; 2019 Jul; 21(7):627-640. PubMed ID: 31100639
[TBL] [Abstract][Full Text] [Related]
35. Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy.
Horne HN; Lee PS; Murphy SK; Alonso MA; Olson JA; Marks JR
Mol Cancer Res; 2009 Feb; 7(2):199-209. PubMed ID: 19208741
[TBL] [Abstract][Full Text] [Related]
36. Hyper-methylation of the upstream CpG island shore is a likely mechanism of GPER1 silencing in breast cancer cells.
Manjegowda MC; Gupta PS; Limaye AM
Gene; 2017 May; 614():65-73. PubMed ID: 28286086
[TBL] [Abstract][Full Text] [Related]
37. CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer.
Zeng Q; Li W; Lu D; Wu Z; Duan H; Luo Y; Feng J; Yang D; Fu L; Yan X
Proc Natl Acad Sci U S A; 2012 Jan; 109(4):1127-32. PubMed ID: 22210108
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic up-regulation of leukemia inhibitory factor (LIF) gene during the progression to breast cancer.
Shin JE; Park SH; Jang YK
Mol Cells; 2011 Feb; 31(2):181-9. PubMed ID: 21191816
[TBL] [Abstract][Full Text] [Related]
39. Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse.
Noetzel E; Rose M; Sevinc E; Hilgers RD; Hartmann A; Naami A; Knüchel R; Dahl E
Oncogene; 2010 Aug; 29(34):4814-25. PubMed ID: 20543860
[TBL] [Abstract][Full Text] [Related]
40. Inactivation of ADAMTS18 by aberrant promoter hypermethylation contribute to lung cancer progression.
Zhang Y; Xu H; Mu J; Guo S; Ye L; Li D; Peng W; He X; Xiang T
J Cell Physiol; 2019 May; 234(5):6965-6975. PubMed ID: 30417422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
